1 Day
Source:
The Boston Globe
_1777370193195_831968492.png&w=48&q=75){kind=small}
AbbVie to acquire Apogee for nearly $11B
AbbVie announced it will acquire Apogee Therapeutics for $10.9 billion in cash, valuing the company at $135.11 per share with a 50 percent premium. The deal focuses on Apogee’s lead drug, zumilokibart, which targets inflammatory conditions such as atopic dermatitis and asthma, and could offer a convenient dosing schedule. This acquisition strengthens AbbVie's position in the immunology field amid increased biotech mergers.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)